July 11, 2016 / 1:53 PM / in a year

BRIEF-Sorrento, Servier enter exclusive worldwide license, collaboration agreement

July 11 (Reuters) - Sorrento Therapeutics

* Sorrento and Servier enter into exclusive worldwide license and collaboration agreement for development and commercialization of anti-PD-1 antibody

* Financial terms of agreement include, among other things, a non-refundable upfront payment to Sorrento of EUR 25 million

* May also receive development milestone payments for initial product and each additional product

* May receive up to EUR 710 million in payments based on commercial sales milestones

* To be entitled to receive royalties on sales of commercialized products ranging from high single-digit to double-digit percentages Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below